Enanta Pharmaceuticals

ENTAPhase 2

Watertown, United StatesFounded 1995enanta.com

Enanta Pharmaceuticals is a publicly traded biotech focused on creating novel oral therapeutics through innovative chemistry, with a proven track record in virology. The company's past success includes collaborating with AbbVie to discover two protease inhibitors (glecaprevir and paritaprevir) that are part of marketed HCV regimens that have cured over one million patients. Its current strategy is to replicate this success in new areas, with a clinical-stage pipeline targeting RSV and earlier-stage immunology programs for type 2 inflammatory diseases. Enanta is led by a seasoned management team and is driven by a mission to transform patient lives with curative therapies.

Market Cap

$363.0M

Founded

1995

Focus

Small Molecules

ENTA · Stock Price

USD 12.5154.41 (-81.31%)

Historical price data

AI Company Overview

Technology Platform

Expertise in medicinal chemistry and structure-based drug design to discover novel oral small-molecule therapeutics targeting viral proteins (e.g., RSV N-protein) and key drivers of the type 2 immune response (KIT, STAT6, MRGPRX2).

Pipeline Snapshot

44 drugs in pipeline

Drug	Indication	Stage
EDP-305 Dose 1 + EDP-305 Dose 2 + Placebo	Non-Alcoholic Steatohepatitis	Phase 2
EDP-938 Dose 1 + EDP-938 Dose 2 + Placebo + EDP-938 Dose 3 + EDP-938 Dose 4 + Pl...	RSV Infection	Phase 2
zelicapavir + Placebo	RSV Infection	Phase 2
EDP-938 + Placebo	Respiratory Syncytial Virus (RSV)	Phase 2
EDP-938 + Placebo	RSV Infection	Phase 2

Funding History

Total raised: $80M

IPO$60MUndisclosedMar 21, 2013

Series A$20MUndisclosedJun 15, 2000

SeedUndisclosedUndisclosedJun 15, 1998

Opportunities

The large, underserved patient populations in RSV and type 2 inflammatory diseases represent multi-billion dollar market opportunities.

Success with its oral RSV treatment could capture a significant share of the treatment market, while its oral immunology platform could disrupt markets currently dominated by injectable biologics, offering superior convenience.

Risk Factors

Key risks include clinical trial failures, particularly for the lead RSV asset; intense competition from approved RSV vaccines/preventatives and immunology biologics; and financial runway dependency on successful data readouts and potential future dilutive financings.

Competitive Landscape

In RSV, competes against GSK/Pfizer vaccines, AstraZeneca/Sanofi's preventative antibody, and other small-molecule developers. In immunology, faces entrenched injectable biologics like dupilumab. Differentiation lies in oral administration, novel mechanisms (N-protein, KIT/STAT6 inhibition), and a high barrier to resistance for its RSV candidate.

Publications

Patents

Pipeline